Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bexmarilimab’s likelihood of approval (LoA) and phase transition for Chronic Myelomonocytic Leukemia (CMML) took place on 27 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 27 Jun 2022 increased Bexmarilimab’s LoA and PTSR for Myelodysplastic Syndrome, increased LoA and PTSR for Refractory Acute Myeloid Leukemia, and increased LoA and PTSR for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bexmarilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bexmarilimab overview

Bexmarilimab is under development for the treatment of hematological tumors including myelodysplastic syndrome, chronic myelomonocytic leukemia, relapsed and refractory acute myeloid leukemia, advanced or metastatic hepatocellular carcinoma, hepatobiliary system tumor, gallbladder cancer, intrahepatic or extrahepatic cholangiocarcinoma, colorectal cancer, anaplastic thyroid cancer, ovarian cancer, pancreatic ductal adenocarcinoma, metastatic uveal melanoma, gastric cancer including adenocarcinoma of the gastroesophageal junction, head and neck cancer squamous cell carcinoma, transitional cell cancer (urothelial cell cancer), metastatic breast cancer, cutaneous melanoma, head and neck cancer squamous cell carcinoma and urothelial cancer. The drug candidate is a humanized monoclonal IgG4 antibody targeting cells expressing CLEVER-1 (Common lymphatic endothelial and vascular endothelial receptor-1). It is administered intravenous and formulation in the form of solution. The drug candidate is based on the composite human antibody technology. The drug candidate is devoid of T cell epitopes which limits mounting of immune reaction against FP-1304.

It was under development for the treatment of renal cell cancer, colon cancer, TAM positive Hodgkin lymphoma, anti-CD20 resistant, lymphoma, tuberculosis, pertussis, glioblastoma, hematological tumor and opportunistic infections.

Faron Pharmaceuticals overview

Faron Pharmaceuticals (Faron) is a clinical stage biopharmaceutical company that develops novel treatments for medical conditions. The company’s clinical pipeline comprise of Traumakine, Bexmarilimab and Haematokine. Its Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. The company’s Haematokine is an investigational Vascular Adhesion Protein 1 (VAP-1) inhibitor which blocks VAP-1 enzymatic activity to supports the expansion of human hematopoietic stem cells. Faron’s receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration as a current pipeline. The company works in collaboration with academic institutions, pharmaceutical companies and contract research organizations for clinical development programmes. Faron is headquartered in Turku, Finland.

Quick View Bexmarilimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Bexmarilimab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.